

## Goat anti-MYO5A Antibody

<b>Item Number</b>	dAP-2173
<b>Target Molecule</b>	Principle Name: MYO5A; Official Symbol: MYO5A; All Names and Symbols: MYO5A; myosin VA (heavy chain 12, myoxin); GS1; MYH12; MYO5; MYR12; dilute; myosin V; myosin VA; myosin, heavy polypeptide kinase; myoxin; Accession Number (s): NP_000250.3; NP_001135967.1; Human Gene ID(s): 4644; Non-Human GeneID(s): 17918 (mouse) 25017 (rat)
<b>Immunogen</b>	ETKQLELDLN, is from internal region This antibody is expected to recognize both reported isoforms (NP_000250.3; NP_001135967.1).
<b>Applications</b>	Pep ELISA, WB, IF  Species Tested: Human, Mouse
<b>Purification</b>	Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
<b>Supplied As</b>	lyophilized powder of 50ug or 100ug IgG; Reconstitute IgG with 100ul or 200ul sterile DI Water and final product will be formulated as 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. Aliquot and store at -20°C. Minimize freezing and thawing.
<b>Peptide ELISA</b>	Peptide ELISA: antibody detection limit dilution 1 to 8000.
<b>Western Blot</b>	Western Blot: Approx 200kDa band observed in lysates of cell line Jurkat (calculated MW of 215kDa according to NP_000250.3). Recommended concentration: 1-3µg/ml.
<b>IHC</b>	
<b>Reference</b>	Reference(s): Guey LT, Garc��a-Closas M, Murta-Nascimento C, Lloreta J, Palencia L, Kogevinas M, Rothman N, Vellalta G, Calle ML, Marenne G, Tard��n A, Carrato A, Garc��a-Closas R, Serra C, Silverman DT, Chanock S, Real FX, Malats N, Genetic susceptibility to distinct bladder cancer subphenotypes.

Optimal dilutions should be determined by each laboratory for each application. The listed dilutions are for recommendation only and the final conditions should be optimized by the ender users! This product is sold for **Research Use Only**